Psychedelics have been the subject of experiments by scientists for decades but went out of favor with the law in the 1960s and 1970s when they “escaped the lab” and were picked up by proselytizers who helped give them a bad name, conference presenters said. This led to a backlash that slammed the lid on research for the next several decades.
The DEA and the U.S. Food and Drug Administration maintain that there is insufficient research to justify recategorization from Schedule I. This stance creates a catch-22 by basing the decision on the need for more research while limiting the ability of scientists to conduct that research. The June report recommends transferring responsibility for drug scheduling from the DEA to another agency or nongovernmental organization without a history of anti-drug bias, such as the U.S. National Academy of Sciences. No matter how it happens, until the drugs are reclassified, bringing psychedelics from research into clinical practice will be an uphill battle.
The study confirms previous research by Imperial College London, that psilocybin, a naturally occurring compound present in “shrooms”, stimulates new brain cell growth and erases frightening memories